For Media: UK Press Releases
This page contains resources intended for journalists only. For media enquiries about our press releases please contact ukmediaenquiries@bayer.com

Bayer's elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies

Mirena® (52mg levonorgestrel IUS) authorised in the UK for extended use up to eight years for contraception



Scottish Medicines Consortium (SMC) recommends two Bayer cancer treatments for use within NHSScotland


17 - 23of 23 News
17 - 23of 23 News